

|   |  |  |  |
|---|--|--|--|
| FORM PTO-1390 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>(REV. 11-2000)  |  | ATTORNEY'S DOCKET NUMBER<br><b>PI4748USW</b>                   |  |
| TRANSMITTAL LETTER TO THE UNITED STATES<br>DESIGNATED/ELECTED OFFICE (DO/EO/US)<br>CONCERNING A FILING UNDER 35 U.S.C. 371  |  | U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR<br><b>10/502261</b> |  |
| INTERNATIONAL APPLICATION NO.<br><b>PCT/GB03/00501</b>  | INTERNATIONAL FILING DATE<br><b>February 5, 2003</b> | PRIORITY DATE CLAIMED<br><b>February 8, 2002</b>               |  |
| TITLE OF INVENTION<br><b>Piperidine Derivatives And Their Use As Antagonists Of Tachykinins</b>   |  |  |  |
| APPLICANT(S) FOR DO/EO/US<br><b>ALVARO, Giuseppe; DI FABIO, Romano</b>  |  |  |  |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:   |  |  |  |
| <ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol> |  |  |  |
| <p><b>Items 13 to 20 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>22. <input checked="" type="checkbox"/> Express Mail Label No. <u>EV 332145999 US</u></li> <li>23. <input checked="" type="checkbox"/> Other items or information:             <ol style="list-style-type: none"> <li>a) PCT Cover Page</li> <li>b) PCT Request</li> </ol> </li> </ol>  |  |  |  |

|  |  |  |
|--|--|--|
| U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR<br><b>10/502261</b> | INTERNATIONAL APPLICATION NO.<br><b>PCT/GB03/00501</b> | ATTORNEY'S DOCKET NUMBER<br><b>PI4748USW</b> |
|--|--|--|

24. The following fees are submitted.:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

|  |           |
|--|-----------|
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... | \$1080.00 |
| <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....  | \$920.00  |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....  | \$770.00  |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....   | \$730.00  |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....   | \$100.00  |

**CALCULATIONS PTO USE ONLY****ENTER APPROPRIATE BASIC FEE AMOUNT =****\$920.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than  20  30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

**\$0.00**

| CLAIMS   | NUMBER FILED | NUMBER EXTRA | RATE                     |                |
|--|--------------|--------------|--------------------------|----------------|
| Total claims                                     | 21 - 20 =    | 1            | x \$18.00                | <b>\$18.00</b> |
| Independent claims                               | 2 - 3 =      | 0            | x \$86.00                | <b>\$0.00</b>  |
| Multiple Dependent Claims (check if applicable). |              |              | <input type="checkbox"/> | <b>\$0.00</b>  |

**TOTAL OF ABOVE CALCULATIONS =** **\$938.00**

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

**SUBTOTAL =** **\$938.00**

Processing fee of **\$130.00** for furnishing the English translation later than  20  30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

**\$0.00****TOTAL NATIONAL FEE =** **\$938.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

**\$0.00****TOTAL FEES ENCLOSED =** **\$938.00**

|  |    |
|--|----|
| <input type="checkbox"/> <b>Amount to be:<br/>refunded</b> | \$ |
| <input type="checkbox"/> <b>charged</b>                    | \$ |

- a.  A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.
- b.  Please charge my Deposit Account No. 07-1392 in the amount of \$938.00 to cover the above fees.
- c.  The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1392
- d.  Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

**23347**

SIGNATURE

**Lorie Ann Morgan**

NAME

**38,181**

REGISTRATION NUMBER

22 Jun 2004  
DATE

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): Alvaro et al.

Docket No.

PI4748USW

| Serial No.<br>To Be Assigned | Filing Date<br>Concurrently Herewith | Examiner<br>To Be Assigned | Group Art Unit<br>To Be Assigned |
|------------------------------|--------------------------------------|----------------------------|----------------------------------|
|------------------------------|--------------------------------------|----------------------------|----------------------------------|

Invention: Piperidine Derivatives And Their Use As Antagonists of Tachykinins

I hereby certify that this Transmittal of National Phase Application With Accompanying Documents  
*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  
37 CFR 1.10 in an envelope addressed to: Director of the United States Patent and Trademark Office, P.O. Box  
1450, Alexandria, VA 22313-1450 on

July 22, 2004*(Date)***Valerie L. Phillips***(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)*EV332145999US*("Express Mail" Mailing Label Number)*